Natera

Natera
Public
Traded as NASDAQ: NTRA
Industry Genetic testing
Headquarters San Carlos, California
Key people
 Matthew Rabinowitz (CEO) Jonathan Sheena (CTO)
Website www.natera.com

Natera (previously Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California.[1] The company specializes in analyzing microscopic quantities of DNA for reproductive health indications to provide preconception and prenatal genetic testing services primarily to OBGYN physicians and in vitro fertilization centers.[2]

In early 2013, the company launched Panorama, a non-invasive prenatal test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation.[3] Other services include tests for preimplantation genetic diagnosis (PGD) and miscarriage testing to determine the cause of the loss of the pregnancy.[4] A non-invasive paternity test based on Natera’s technology, was brought to market in August 2011 through a partnership with DNA Diagnostics Center (DDC), which holds a license to the technology in the United States.[5] In 2016, Dr. Susan Gross stepped aside as Natera's chief medical officer.

Panorama Test

Natera launched a non-invasive prenatal test (NIPT) in February 2013 called Panorama that uses an advanced bioinformatics-based algorithm to analyze the cell-free fetal DNA that is found in the mother’s blood. Panorama detects chromosome abnormalities, including Trisomy 21, the cause of Down syndrome, Trisomy 18, the cause of Edwards syndrome, Trisomy 13, the cause of Patau syndrome, sex chromosome abnormalities, triploidy and certain microdeletions as early as the first trimester of pregnancy.[6][7][8] A clinical study evaluating Natera’s NIPT is funded by the National Institutes of Health and is currently ongoing.

Competition

Companies also offering non-invasive prenatal genetic testing include Sequenom, Ariosa (Harmony Prenatal Test), Ravgen, and Verinata Health. Other companies and universities that are working towards developing non-invasive prenatal testing include Stanford University,[9] Fluidigm and Ikonisys.

Peer-Reviewed Articles

  • Nicolaides, KH; et al. (Oct 10, 2013). "Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood.". Fetal Diagn Ther. 35 (3): 212–7. doi:10.1159/000355655. PMID 24135152. 
  • Nicolaides, KH; et al. (June 2013). "Validation of targeted sequencing of single-nucleotide polymorphism for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X and Y.". Prenat Diag. 33 (6): 575–9. doi:10.1002/pd.4103. PMID 23613152. 
  • Canick, JA; et al. (July 2013). "The impact of maternal fetal plasma DNA fetal fraction on next generation sequencing test for common fetal aneuploidies.". Prenat Diag. 33 (7): 667–74. doi:10.1002/pd.4126. PMID 23592541. 

References

This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.